Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Retrospective study of the impact of ocrelizumab used in patients with multiple sclerosis
研究概览
简要总结
Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease; clinical events are mainly attributed to myelin destruction and inflammatory of the central nervous system.
The diagnosis resides in clinical and radiological criteria according to 2017 McDonald criteria.
Once the diagnosis of MS has been made, treatment should be initiated promptly, in order to delay the onset of severe disability in the long-term, even more ocrelizumab are a treatment of high efficacy.
Ocrelizumab is used as a first-line or second-line treatment in Relapsing Remitting MS (RRMS) It is an anti-CD20 monoclonal antibody that provides rapid depletion of circulating CD20+ B lymphocytes by complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.
The main objective is the retrospective evaluation of the impact of ocrelizumab on the outcome of MS.
The secondary objective is the search of predictive factors of response to treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Retrospective study of the impact of ocrelizumab used in patients with multiple sclerosis
时间窗: Files analysed retrospectively from October 01, 2018 to November 31, 2020 will be examined]
次要结局
未报告次要终点